Outlook and Goals 2026

Acceleration Through Process Optimisation

The first measurable effects of the new overarching strategy are expected to become visible in 2026. The Swiss Cancer Institute is planning to activate 15 to 20 new clinical cancer trials. A significant share of these activations is already planned for the first half of the year.

This would mark a new record in the number of trial activations in the Institute’s more than 60-year history.

In addition, our goal is to have at least one trial open for patient enrolment in each research group and across all cancer types by the end of 2026. This will strengthen research activity across the entire network and increase the visibility of clinical research at all participating centres.

The continuous optimisation of internal processes remains a key priority. The modular trial components that were successfully tested in four pilot trials last year will be rolled out to all trials in 2026.

This structure increases transparency, enables more targeted selection of mandatory trial elements and reduces time and costs for both researchers and the Institute.

Particular attention is being given to contract management. Additional potential for process acceleration has been identified in this area in order to sustainably speed up the activation of new trials.

Collaboration as a Key Success Factor

Close and trust-based collaboration between the Competence Centre in Bern, the researchers and the member centres remains a key foundation for the Institute’s continued development.

Organisational culture, dialogue and collaborative coordination are central pillars of our work. This institutional stability enables us to combine ambitious growth targets with operational reliability.

Research Alliances and Strategic Partnerships

Another key focus in 2026 will be the consolidation of existing research alliances and the expansion of new partnerships.

The structured alignment of research strategies with industry partners has proven to be an effective instrument.

Several investigator-initiated trials are currently at an advanced stage of discussion, with the aim of launching them this year.

In addition, there are plans to conduct more therapy optimisation trials in collaboration with health insurance providers. Initial discussions have already begun.

Innovation: Gender Medicine and Artificial Intelligence

The Swiss Cancer Institute will further expand its activities in the field of gender medicine. Together with partners and contributors, new research approaches are being developed and structurally embedded within the Institute’s research framework.

At the same time, the use of artificial intelligence to support research and operational processes is becoming increasingly important. AI-based applications are intended to improve efficiency, data analysis and decision-making in a targeted manner.

Visibility and Political Responsibility

Alongside its operational and scientific development, the Swiss Cancer Institute’s institutional visibility will be further strengthened in 2026. The aim is to communicate the societal relevance and impact of clinical cancer research in a transparent way.

As a research institution of national importance, the SCI will continue to actively advocate for improved framework conditions for clinical research in Switzerland.

Within the framework of the National Cancer Plan, the Institute is taking the lead in the area of clinical cancer research. The goal is to systematically raise awareness of its importance among policymakers, the public and other stakeholders, and to secure long-term support.